These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 24728998)

  • 1. Classification and evolution of type II CRISPR-Cas systems.
    Chylinski K; Makarova KS; Charpentier E; Koonin EV
    Nucleic Acids Res; 2014 Jun; 42(10):6091-105. PubMed ID: 24728998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phylogenomics of Cas4 family nucleases.
    Hudaiberdiev S; Shmakov S; Wolf YI; Terns MP; Makarova KS; Koonin EV
    BMC Evol Biol; 2017 Nov; 17(1):232. PubMed ID: 29179671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.
    Fonfara I; Le Rhun A; Chylinski K; Makarova KS; Lécrivain AL; Bzdrenga J; Koonin EV; Charpentier E
    Nucleic Acids Res; 2014 Feb; 42(4):2577-90. PubMed ID: 24270795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobile Genetic Elements and Evolution of CRISPR-Cas Systems: All the Way There and Back.
    Koonin EV; Makarova KS
    Genome Biol Evol; 2017 Oct; 9(10):2812-2825. PubMed ID: 28985291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidelity of prespacer capture and processing is governed by the PAM-mediated interactions of Cas1-2 adaptation complex in CRISPR-Cas type I-E system.
    Yoganand KN; Muralidharan M; Nimkar S; Anand B
    J Biol Chem; 2019 Dec; 294(52):20039-20053. PubMed ID: 31748409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR adaptive immune systems of Archaea.
    Vestergaard G; Garrett RA; Shah SA
    RNA Biol; 2014; 11(2):156-67. PubMed ID: 24531374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas: Adapting to change.
    Jackson SA; McKenzie RE; Fagerlund RD; Kieper SN; Fineran PC; Brouns SJ
    Science; 2017 Apr; 356(6333):. PubMed ID: 28385959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cas4/1 dual nuclease activities enable prespacer maturation and directional integration in a type I-G CRISPR-Cas system.
    Dhingra Y; Sashital DG
    J Biol Chem; 2023 Sep; 299(9):105178. PubMed ID: 37607619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity and evolution of class 2 CRISPR-Cas systems.
    Shmakov S; Smargon A; Scott D; Cox D; Pyzocha N; Yan W; Abudayyeh OO; Gootenberg JS; Makarova KS; Wolf YI; Severinov K; Zhang F; Koonin EV
    Nat Rev Microbiol; 2017 Mar; 15(3):169-182. PubMed ID: 28111461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.
    Silas S; Makarova KS; Shmakov S; Páez-Espino D; Mohr G; Liu Y; Davison M; Roux S; Krishnamurthy SR; Fu BXH; Hansen LL; Wang D; Sullivan MB; Millard A; Clokie MR; Bhaya D; Lambowitz AM; Kyrpides NC; Koonin EV; Fire AZ
    mBio; 2017 Jul; 8(4):. PubMed ID: 28698278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
    He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
    Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.
    Xiao Y; Ng S; Nam KH; Ke A
    Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPRCasdb a successor of CRISPRdb containing CRISPR arrays and cas genes from complete genome sequences, and tools to download and query lists of repeats and spacers.
    Pourcel C; Touchon M; Villeriot N; Vernadet JP; Couvin D; Toffano-Nioche C; Vergnaud G
    Nucleic Acids Res; 2020 Jan; 48(D1):D535-D544. PubMed ID: 31624845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unprecedented Diversity of Unique CRISPR-Cas-Related Systems and Cas1 Homologs in Asgard Archaea.
    Makarova KS; Wolf YI; Shmakov SA; Liu Y; Li M; Koonin EV
    CRISPR J; 2020 Jun; 3(3):156-163. PubMed ID: 33555973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The subtype I-F CRISPR-Cas system influences pathogenicity island retention in Pectobacterium atrosepticum via crRNA generation and Csy complex formation.
    Richter C; Fineran PC
    Biochem Soc Trans; 2013 Dec; 41(6):1468-74. PubMed ID: 24256239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annotation and Classification of CRISPR-Cas Systems.
    Makarova KS; Koonin EV
    Methods Mol Biol; 2015; 1311():47-75. PubMed ID: 25981466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ISC, a Novel Group of Bacterial and Archaeal DNA Transposons That Encode Cas9 Homologs.
    Kapitonov VV; Makarova KS; Koonin EV
    J Bacteriol; 2015 Dec; 198(5):797-807. PubMed ID: 26712934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate generation for endonucleases of CRISPR/cas systems.
    Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
    J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casposons: a new superfamily of self-synthesizing DNA transposons at the origin of prokaryotic CRISPR-Cas immunity.
    Krupovic M; Makarova KS; Forterre P; Prangishvili D; Koonin EV
    BMC Biol; 2014 May; 12():36. PubMed ID: 24884953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.